I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Behcet’s Disease and the Retina: A Patient Guide
Understanding Behcet's Disease
Behcet's disease is a chronic autoimmune disorder that causes inflammation in blood vessels throughout the body. It affects multiple organ systems, often in cycles of flare-ups and quiet periods, making ongoing medical care an essential part of managing it well.
In autoimmune conditions, the body's immune system mistakenly attacks its own healthy tissues. In Behcet's disease, this attack targets blood vessels of all sizes in a process known as vasculitis (inflammation of the blood vessels). The result is inflammation that can appear across many parts of the body, including the eyes, mouth, skin, and other organ systems.
The hallmark signs of Behcet's disease include painful mouth sores (oral aphthous ulcers), genital ulcers, skin lesions, and eye inflammation. Because these symptoms can involve so many systems at once, Behcet's is classified as a multisystemic disorder. The disease tends to follow a pattern of recurring flare-ups separated by quieter periods.
Eye involvement occurs in a significant portion of patients with Behcet's disease. When the eyes are affected, the condition causes uveitis, which is inflammation of the uvea (the middle layer of the eye wall). The most common form is panuveitis, meaning inflammation that involves both the front and the back portions of the eye simultaneously.
Inside the eye, white blood cells infiltrate the blood vessels of the retina, leading to retinal vasculitis (inflammation of the small blood vessels that supply the retina). This process can cause vessel blockages, swelling in the macula (the central part of the retina responsible for sharp detail vision), and progressive damage to the delicate tissue layers that support clear sight.
Eye inflammation can be the first sign of Behcet's disease in some patients, appearing before other symptoms develop. Without prompt treatment, repeated episodes of inflammation can cause cumulative and potentially permanent damage to the retina. Each flare-up carries the risk of leaving behind lasting injury to the structures that support vision.
Early diagnosis and consistent treatment are the most important factors in protecting long-term visual function. Patients who begin effective therapy early tend to have better outcomes than those whose treatment is delayed.
Who Is at Risk
Behcet's disease is relatively rare in the United States and other Western countries, but it occurs more frequently in certain populations around the world. Understanding who is most at risk can help patients and their care teams stay alert to early signs of the condition.
Behcet's disease is most common in countries along the ancient Silk Road trade route, which stretches from eastern Asia through the Middle East to the Mediterranean. Countries such as Turkey, Iran, and Japan have much higher rates of the disease compared to Western nations. In Japan, Behcet's disease remains one of the leading causes of blindness, underscoring how serious the eye involvement can become without aggressive treatment.
The strongest known genetic risk factor for Behcet's disease is a gene variant called HLA-B51 (also referred to as HLA-B5). People who carry this variant have a notably higher chance of developing the condition. HLA-B51 is more common in Turkish, Middle Eastern, and Japanese populations, which helps explain the geographic patterns in disease rates.
Genetic testing for HLA-B51 can support a diagnosis, though carrying the gene alone does not confirm the disease. Most people who have HLA-B51 never develop Behcet's disease at all.
Behcet's disease typically develops in adults between the ages of 20 and 40. Males tend to develop more severe forms of the disease, including eye involvement, blood vessel clots (thrombophlebitis), and neurological complications.
Several factors are associated with a higher risk of poor vision outcomes in patients with ocular Behcet's disease:
- Younger age at the time of diagnosis
- Male gender
- Presence of skin lesions or joint inflammation (arthritis)
- Neurological involvement
- Blood vessel clots (vascular thromboses)
- Frequent episodes of posterior uveitis, meaning inflammation at the back of the eye
- Dense clouding of the vitreous (the clear gel that fills the interior of the eye)
- Inflammatory deposits on the surface of the retina (retinal infiltrates)
Recognizing the Symptoms
The symptoms of ocular Behcet's disease vary depending on which part of the eye is inflamed. Some forms cause obvious, painful symptoms, while others can quietly damage the retina with very little warning. Knowing what to watch for is an important part of protecting your vision.
Anterior uveitis is inflammation in the front portion of the eye, including the iris (the colored ring around the pupil). This form tends to produce more noticeable symptoms, including eye pain, redness in the white of the eye, sensitivity to light (photophobia), excessive tearing, and blurred or reduced vision.
A distinctive finding in Behcet's disease is a condition called hypopyon, a visible layer of white blood cells that settles at the bottom of the front chamber of the eye. This finding was one of the original signs described when the disease was first identified. It occurs in roughly one-third of cases and, while alarming in appearance, is sterile, meaning it is caused by inflammation rather than infection.
Posterior uveitis involves inflammation in the back of the eye, including the retina and the vitreous (the gel-like substance that fills the eye). This form is often more dangerous because it can progress and damage the retina while producing relatively mild or subtle symptoms.
Patients may notice a painless decrease in vision, new floaters (spots, threads, or cobwebs drifting across the visual field), or blank areas in their peripheral (side) vision. Because posterior uveitis may not cause the obvious pain and redness associated with front-eye inflammation, its severity can be easy to underestimate.
During a dilated eye examination, a retina specialist looks for specific signs of active Behcet's disease. These include cells and protein (called flare) floating in the front chamber of the eye, cloudiness or haziness in the vitreous gel, and a whitish coating or leakage around retinal blood vessels (vascular sheathing).
The specialist also checks for vitritis (inflammation within the vitreous), retinitis (direct inflammation of retinal tissue), papillitis (swelling of the optic nerve head at the back of the eye), and macular edema (fluid-related swelling in the center of the retina). Identifying these findings helps determine the extent of disease activity and guides treatment decisions.
Diagnosis and Testing
There is no single blood test that can confirm Behcet's disease on its own. Diagnosis relies on identifying a characteristic pattern of findings across multiple organ systems, often requiring input from several medical specialists working together.
The diagnosis of Behcet's disease is based on clinical criteria. Recurrent oral ulcers are typically required as a central feature. In addition, at least two of the following must be present: genital ulcers, eye inflammation (uveitis), skin lesions, or a positive pathergy test (an exaggerated skin reaction to a minor needle prick that is more common in patients with this condition).
Blood tests are often ordered to rule out other inflammatory or infectious conditions that can look similar to Behcet's disease. Genetic testing for HLA-B51 may be used as a supporting element of the diagnostic picture, but is not conclusive on its own.
A thorough dilated eye examination is the foundation of evaluating eye involvement in Behcet's disease. A retina specialist uses a slit lamp (a specialized microscope) to examine the front and back of the eye in close detail.
Optical coherence tomography (OCT) is a non-invasive imaging scan that creates detailed, cross-sectional images of the retina, helping detect macular edema and retinal thinning. Fluorescein angiography, in which a special dye is injected into a vein and photographs of the retinal blood vessels are taken in sequence, reveals areas of leakage, blockage, and active vasculitis. Together, these tools give our specialists a clear picture of how much damage has occurred and how the disease is responding to treatment.
Because Behcet's disease affects many organ systems, care typically involves a coordinated team of physicians. A rheumatologist (a specialist in autoimmune and inflammatory diseases) usually manages the overall disease and prescribes systemic medications. A retina specialist focuses on protecting the eyes and managing ocular complications.
Depending on other symptoms, a dermatologist, neurologist, or vascular specialist may also be involved. Good communication among all members of your care team is essential for consistent and effective disease management over time.
Treatment Options
Treatment for ocular Behcet's disease focuses on controlling active inflammation as quickly as possible and then maintaining long-term suppression to reduce the risk of future flare-ups. The right combination of therapies depends on the severity of disease, the parts of the eye involved, and each patient's individual health circumstances.
Corticosteroids are the primary first-response treatment when active eye inflammation is present. For inflammation limited to the front of the eye, corticosteroid eye drops may be sufficient. For more severe inflammation involving the back of the eye, such as posterior uveitis or panuveitis, oral or injectable corticosteroids are often necessary to reduce inflammation quickly and protect the retina.
While corticosteroids are highly effective for short-term control, long-term use carries significant risks. These include elevated eye pressure (which can lead to glaucoma), cataract formation, weight gain, bone thinning, and elevated blood sugar. For this reason, corticosteroids are generally used as a bridge while longer-lasting therapies are started.
Because Behcet's disease is chronic and recurrent, most patients with eye involvement require long-term immunosuppressive therapy. These are medications that calm an overactive immune response to reduce the frequency and severity of flare-ups. Azathioprine is generally considered a first-line choice for patients with ocular involvement.
Other commonly used immunosuppressants include cyclosporine, which targets specific immune cells involved in inflammation, and methotrexate, which broadly reduces immune system activity. These medications are often used alongside or as replacements for corticosteroids to maintain disease control over time while reducing steroid-related side effects.
Biologic therapies are a newer class of medications that target specific proteins in the immune system responsible for triggering inflammation. Anti-tumor necrosis factor (anti-TNF) agents have significantly improved outcomes for patients with ocular Behcet's disease, particularly those who do not respond adequately to conventional immunosuppressants.
Two anti-TNF agents commonly used in this setting are infliximab and adalimumab. Research comparing these two medications in patients with Behcet's-related uveitis has shown that both can meaningfully improve outcomes, with some evidence suggesting adalimumab may offer advantages in certain measures of disease control. Interferon-alpha is another biologic option that has demonstrated effectiveness in managing ocular Behcet's disease.
Apremilast is an oral medication that works by inhibiting a specific enzyme (phosphodiesterase 4) involved in the inflammatory process. It is the first treatment approved by the U.S. Food and Drug Administration specifically for oral ulcers in adults with Behcet's disease. Its role in managing broader aspects of the condition, including eye involvement, is an active area of investigation.
Additional biologic agents targeting other immune pathways are being studied for patients whose disease does not respond to standard therapies. Treatment decisions are always made by your physician based on your individual disease activity, other health conditions, and response to prior therapy. No single treatment approach is right for every patient.
Managing Life With Behcet's Disease
Behcet's disease is a long-term condition that requires consistent attention and care. Understanding what to expect day to day, and knowing when to seek urgent help, can make a meaningful difference in protecting your vision over time.
Behcet's disease follows a pattern of active flare-ups alternating with quieter periods of remission. The frequency and severity of these cycles vary considerably from person to person. Some patients experience occasional mild episodes, while others face frequent and severe attacks that pose a serious risk to vision.
Each inflammatory episode carries the potential for cumulative retinal damage. The goal of treatment is to reduce both the frequency and severity of flare-ups over the long term. With modern immunosuppressive and biologic therapies, many patients now achieve better disease control than was possible in earlier decades of treatment.
Immunosuppressive medications often take several weeks to reach their full therapeutic effect. During this period, corticosteroids may be used as a bridge to control active inflammation. Regular follow-up with a retina specialist is essential throughout this process, typically every few weeks during active disease and every few months during stable periods.
Monitoring visits usually include a dilated eye exam, OCT imaging, and sometimes fluorescein angiography. Blood tests may also be needed periodically to check for medication side effects. Consistent follow-up is especially important because posterior uveitis can progress silently, without obvious symptoms, making it easy to miss a recurrence.
Patients with ocular Behcet's disease should pay close attention to any changes in their vision, even subtle ones. Wearing sunglasses outdoors can help manage light sensitivity during or following a flare-up. All prescribed eye drops and systemic medications should be used exactly as directed, and no medication should be stopped or adjusted without guidance from your treating physician.
Keeping a simple symptom log can help you and your care team identify patterns in your disease activity over time. While no specific lifestyle change has been proven to prevent Behcet's flare-ups, managing stress, getting adequate sleep, and maintaining overall health may support your body's ability to tolerate treatment and recover from episodes.
Certain changes in vision require immediate attention. If you have been diagnosed with Behcet's disease or have a history of uveitis, contact a retina specialist right away or go to an emergency room if you experience any of the following:
- Sudden decrease in vision in one or both eyes
- A significant and sudden increase in floaters (spots or threads drifting through your vision)
- Flashes of light in your visual field
- A shadow or dark curtain appearing over part of your vision
- New or worsening eye pain with redness
These symptoms may signal a severe inflammatory flare-up, retinal vasculitis, or a retinal complication that requires prompt evaluation and treatment. Do not wait to see if symptoms resolve on their own.
Living with a rare chronic disease can be emotionally demanding. Concerns about potential vision loss, the burden of frequent medical appointments, and the side effects of long-term medications can all take a meaningful toll. Support groups for patients with Behcet's disease, available both in person and online, can provide valuable connections with others facing similar challenges. Speaking with a counselor or therapist may also help you manage the psychological weight that comes with a chronic illness diagnosis.
Frequently Asked Questions
These answers address common questions from patients and families navigating a Behcet's disease diagnosis for the first time.
At this time, Behcet's disease cannot be cured, but it can be effectively managed in many patients. The goal of treatment is to suppress inflammation, extend periods of remission, and prevent serious complications such as vision loss. Some patients achieve long, stable periods of good disease control with appropriate therapy. Your care team will adjust your treatment over time based on how your disease behaves and how well you respond to different medications.
Not every patient with ocular Behcet's disease experiences significant vision loss. Outcomes depend heavily on how quickly treatment begins, how well inflammation responds to therapy, and how often flare-ups occur. The introduction of biologic therapies has meaningfully improved visual outcomes compared to older treatment approaches. Delayed treatment or frequent uncontrolled episodes increase the risk of permanent retinal damage, which is why consistent follow-up care is one of the most important things you can do to protect your sight.
Most patients with ocular Behcet's disease require immunosuppressive therapy for many years, and some may need it indefinitely. Your physicians will periodically assess whether it is safe to reduce or adjust your medications based on your disease activity and overall health. Stopping treatment on your own, or reducing doses without medical guidance, can trigger a damaging flare-up even when the disease has felt quiet for an extended period.
Behcet's disease is not contagious and cannot be passed from person to person. While certain gene variants, particularly HLA-B51, are associated with higher risk, the condition does not follow a straightforward inheritance pattern. Having a family member with Behcet's disease may modestly increase your personal risk, but the vast majority of people who carry the associated gene variants never develop the condition. Environmental factors are thought to play a role as well, though they are not yet fully understood.
Anterior uveitis involves the front of the eye and usually produces noticeable symptoms such as pain, redness, and light sensitivity, making it easier to recognize as a problem. Posterior uveitis involves the back of the eye, including the retina and vitreous, and can be more dangerous precisely because it tends to cause fewer obvious warning signs. Many patients with ocular Behcet's disease develop panuveitis, which affects both the front and back of the eye at the same time. Because posterior inflammation may progress without pain or visible redness, scheduled examinations with a retina specialist are critical even when your eyes feel comfortable.
Yes. While many patients come to us through referrals from their rheumatologist, primary care physician, or general eye doctor, we also welcome patients who reach out directly. If you have been diagnosed with Behcet's disease and have not yet seen a retina specialist, or if you are experiencing new or worsening eye symptoms, you do not need to wait for a formal referral to schedule an evaluation. Prompt assessment is always appropriate when there is any concern about retinal health.
See Our Team for Expert Retina Care
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons have extensive experience evaluating and managing complex inflammatory conditions like ocular Behcet's disease. We offer advanced diagnostic imaging, including OCT and fluorescein angiography, and coordinate closely with your other treating physicians to build a care plan tailored to your needs. If you are in Connecticut and have concerns about your retinal health, we encourage you to reach out and take the next step toward protecting your vision.
30 Years of Care & Commitment
